• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
68 results

Apotex Inc. v. Pfizer Inc.

Docket IPR2021-01132, Patent Trial and Appeal Board (June 17, 2021)

cite Cite Docket

11 Notice refund approved: Notice refund approved

Document IPR2021-01132, No. 11 Notice refund approved - Notice refund approved (P.T.A.B. Nov. 5, 2021)
Patent 6,890,927 Mailed: November 5, 2021
Petitioner’s request for a refund of certain post-institution fees paid on June 17 2021, in the above proceeding is hereby granted.
The amount of $22,500.00 has been refunded to Petitioner’s deposit account.
The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in the Patent Trial and Appeal Board End to End (PTAB E2E), accessible from the Board Web site at http://www.uspto.gov/PTAB.
cite Cite Document

9 Termination Decision Pre DI settlement: Termination Decision Decision Settlemen...

Document IPR2021-01132, No. 9 Termination Decision Pre DI settlement - Termination Decision Decision Settlement Prior to Institution of Trial (P.T.A.B. Oct. 29, 2021)

cite Cite Document

5 Notice of Filing Date Accorded to Petition: Notice of Accord Filing Date

Document IPR2021-01132, No. 5 Notice of Filing Date Accorded to Petition - Notice of Accord Filing Date (P.T.A.B. Jul. 12, 2021)
For more information, please consult the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012), which is available on the Board Web site at http://www.uspto.gov/PTAB.
Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.
The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel pro hac vice requires a showing of good cause.
Many non-profit organizations, both inside and outside the intellectual property field, offer alternative dispute resolution services.
If the parties actually engage in alternative dispute resolution, the PTAB would be interested to learn what mechanism (e.g., arbitration, Case IPR2021-01132 Patent No. 6,890,927 B2 mediation, etc.) was used and the general result.
cite Cite Document

8 Motion: Joint Motion to Terminate

Document IPR2021-01132, No. 8 Motion - Joint Motion to Terminate (P.T.A.B. Oct. 21, 2021)
Pursuant to 37 C.F.R. § 42.74(b), the Parties’ settlement agreement made in contemplation of termination of this proceeding is in writing, and a true and correct copy of such document is being filed herewith as Petitioner’s Exhibit 1025.
The Parties hereby jointly request that the settlement agreement at Petitioner’s Exhibit 1025 be treated as business confidential information, and be kept separate from the files of the above captioned IPR pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).
On the same day (October 19, 2021), the Parties informed the Board of settlement and requested authorization to file a joint motion to terminate the proceeding with respect to both Apotex and Pfizer.
The Board additionally authorized the Parties to include with the joint motion to terminate a request to treat the settlement as business confidential information.
1022 Stahl 1023 Pharmeuropa 2000 1024 Aakeroy G. Steffen Paulekuhn et al., Trends in Active Pharmaceutical Ingredient Salt Selection Based on Analysis of the Orange Book Database, 50 J.
cite Cite Document

1 Petition: Petition

Document IPR2021-01132, No. 1 Petition - Petition (P.T.A.B. Jun. 17, 2021)

cite Cite Document

10 Refund Request: Petitioner Apotex Inc Request for Refund of Post Institution Fe...

Document IPR2021-01132, No. 10 Refund Request - Petitioner Apotex Inc Request for Refund of Post Institution Fees (P.T.A.B. Nov. 2, 2021)

cite Cite Document

7 Notice: Patent Owners Update to Mandatory Notice

Document IPR2021-01132, No. 7 Notice - Patent Owners Update to Mandatory Notice (P.T.A.B. Oct. 19, 2021)

cite Cite Document
1 2 3 4 5 >>